Fate Therapeutics Ownership | Who Owns Fate Therapeutics?

Overview Forecast RevenueFinancials Chart Transcripts

Fate Therapeutics Ownership Summary

Fate Therapeutics is owned by 97.34% institutional investors, 2.17% insiders, and 0.48% retail investors. Redmile group is the largest institutional shareholder, holding 13.03% of FATE shares. BB Biotech AG Ord is the top mutual fund, with 4.25% of its assets in Fate Therapeutics shares.

FATE Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Fate Therapeutics	97.34%	2.17%	0.48%
Sector	Healthcare Stocks	49.73%	8.84%	41.43%
Industry	Biotech Stocks	47.04%	8.74%	44.21%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Redmile group	13.17M	13.03%	$43.19M
Vanguard group	10.57M	10.45%	$34.67M
Blackrock	10.12M	10.01%	$33.18M
Boxer capital	8.22M	8.13%	$26.95M
Deep track capital, lp	5.57M	5.51%	$18.28M
State street	5.34M	5.28%	$17.51M
Bellevue group	4.84M	4.79%	$15.87M
D. e. shaw	4.08M	4.03%	$13.38M
Deerfield management company, l.p. (series c)	3.56M	3.52%	$11.66M
Johnson & johnson	3.38M	3.34%	$11.08M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Johnson & johnson	3.38M	2.77%	$11.08M
Redmile group	13.17M	2.61%	$43.19M
Superstring capital management lp	497.36K	2.06%	$1.63M
Boxer capital	8.22M	1.42%	$26.95M
Deep track capital, lp	5.57M	0.55%	$18.28M
Vestal point capital, lp	2.00M	0.49%	$6.56M
Bruce	300.00K	0.32%	$984.00K
Integral health asset management	850.00K	0.26%	$2.79M
Bellevue group	4.84M	0.26%	$15.87M
Gcm grosvenor	495.92K	0.24%	$1.63M

Top Buyers

Holder	Shares	% Assets	Change
Deerfield management company, l.p. (series c)	3.56M	0.19%	1.37M
D. e. shaw	4.08M	0.01%	1.35M
Vestal point capital, lp	2.00M	0.49%	1.20M
Baker bros. advisors lp	3.00M	0.13%	1.18M
Dimensional fund advisors lp	2.13M	0.00%	1.07M

Top Sellers

Holder	Shares	% Assets	Change
State street	5.34M	0.00%	-2.70M
Suvretta capital management	-	-	-2.56M
Holocene advisors, lp	-	-	-2.53M
Point72 asset management	-	-	-1.58M
Adage capital partners gp	870.00K	0.01%	-1.27M

New Positions

Holder	Shares	% Assets	Change	Value
Renaissance	548.54K	0.00%	548.54K	$1.80M
Perceptive advisors	345.57K	0.03%	345.57K	$1.13M
Ubs asset management americas	188.46K	0.00%	188.46K	$618.15K
Swiss national bank	179.10K	0.00%	179.10K	$587.45K
Thrivent financial for lutherans	100.57K	0.00%	100.57K	$330.00K

Sold Out

Holder	Change
Mather group, llc.	-5.00
Innealta capital	-9.00
Chris bulman	-10.00
Nelson, van denburg & campbell wealth management group	-17.00
Evermay wealth management	-25.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Sep 30, 2024	163	-9.94%	114,640,778	-6.17%	97	0.67%	63	-33.68%	57	18.75%
Jun 30, 2024	181	7.74%	122,176,866	-0.69%	120	0.82%	95	6.74%	48	-5.88%
Mar 31, 2024	168	7.01%	123,027,798	29.12%	121	1.30%	89	32.84%	51	-15.00%
Dec 31, 2023	157	-5.99%	95,280,535	-0.40%	96	1.03%	67	-16.25%	60	20.00%
Sep 30, 2023	167	-11.64%	95,660,318	-12.34%	97	0.79%	80	-14.89%	50	-10.71%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
BB Biotech AG Ord	4.84M	4.25%	-
Vanguard Total Stock Mkt Idx Inv	3.05M	2.68%	-
iShares Russell 2000 ETF	2.78M	2.44%	-5.81K
Vanguard Strategic Equity Inv	2.54M	2.23%	-212.33K
SPDR® S&P Biotech ETF	2.35M	2.06%	-71.37K
Vanguard Institutional Extnd Mkt Idx Tr	1.40M	1.23%	-5.28K
Vanguard Explorer Inv	1.27M	1.11%	-
Fidelity Small Cap Index	1.02M	0.90%	-7.15K
iShares Russell 2000 Value ETF	972.11K	0.85%	1.26K
BlackRock Advantage Small Cap Core Instl	943.41K	0.83%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Aug 06, 2024	Xu Yuan	-	Sell	$2.68K
Mar 04, 2024	Dulac Edward J III	Chief Financial Officer	Sell	$19.01K
Jan 29, 2024	Dulac Edward J III	Chief Financial Officer	Sell	$9.24K
Jan 09, 2024	TAHL CINDY	General Counsel and Secretary	Sell	$47.52K
Jan 09, 2024	Valamehr Bahram	Chief R&D Officer	Sell	$49.37K

Insider Transactions Trends

Date	Buy	Sell
2024 Q3	-	1
2024 Q2	-	-
2024 Q1	-	7
2023 Q4	1	2
2023 Q3	-	4

FATE Ownership FAQ

Who Owns Fate Therapeutics?

Fate Therapeutics shareholders are primarily institutional investors at 97.34%, followed by 2.17% insiders and 0.49% retail investors. The average institutional ownership in Fate Therapeutics's industry, Biotech Stocks , is 47.04%, which Fate Therapeutics exceeds.

Who owns the most shares of Fate Therapeutics?

Fate Therapeutics’s largest shareholders are Redmile group (13.17M shares, 13.03%), Vanguard group (10.57M shares, 10.45%), and Blackrock (10.12M shares, 10.01%). Together, they hold 33.49% of Fate Therapeutics’s total shares outstanding.

Does Blackrock own Fate Therapeutics?

Yes, BlackRock owns 10.01% of Fate Therapeutics, totaling 10.12M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 33.18M$. In the last quarter, BlackRock increased its holdings by 1.02M shares, a 11.17% change.

Who is Fate Therapeutics’s biggest shareholder by percentage of total assets invested?

Johnson & johnson is Fate Therapeutics’s biggest shareholder by percentage of total assets invested, with 2.77% of its assets in 3.38M Fate Therapeutics shares, valued at 11.08M$.

Who is the top mutual fund holder of Fate Therapeutics shares?

BB Biotech AG Ord is the top mutual fund holder of Fate Therapeutics shares, with 4.25% of its total shares outstanding invested in 4.84M Fate Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools